Published in Osteoporos Int on January 12, 2012
Vitamin D levels and response to biphosphonates in postmenopausal women receiving glucocorticoid therapy. Osteoporos Int (2014) 5.05
Vitamin D and bisphosphonate response. Osteoporos Int (2014) 5.04
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res (2016) 1.50
Influence of drugs on vitamin D and calcium metabolism. Dermatoendocrinol (2012) 1.02
Vitamin D and bone disease. Biomed Res Int (2012) 0.98
Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis. Ther Adv Neurol Disord (2013) 0.89
Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis. J Bone Miner Metab (2015) 0.85
Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis. Osteoporos Int (2014) 0.85
The impact of dietary calcium intake and vitamin D status on the effects of zoledronate. Osteoporos Int (2012) 0.84
Silicon: a review of its potential role in the prevention and treatment of postmenopausal osteoporosis. Int J Endocrinol (2013) 0.83
Effect of vitamin D status on pharmacological treatment efficiency: Impact on cost-effective management in medicine. Dermatoendocrinol (2013) 0.80
Micronutrients in Oncological Intervention. Nutrients (2016) 0.77
Emphasizing the health benefits of vitamin D for those with neurodevelopmental disorders and intellectual disabilities. Nutrients (2015) 0.77
Effect of vitamin D status on pharmacological treatment efficiency: Impact on cost-effective management in medicine. Dermatoendocrinol (2013) 0.75
Oral Calcidiol Is More Effective Than Cholecalciferol Supplementation to Reach Adequate 25(OH)D Levels in Patients with Autoimmune Diseases Chronically Treated with Low Doses of Glucocorticoids: A "Real-Life" Study. J Osteoporos (2015) 0.75
Efficacy of a Once-Monthly Pill Containing Ibandronate and Cholecalciferol on the Levels of 25-Hydroxyvitamin D and Bone Markers in Postmenopausal Women with Osteoporosis. Endocrinol Metab (Seoul) (2014) 0.75
Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan. Osteoporos Int (2014) 0.75
Characteristics associated with bone mineral density responses to alendronate in men. Calcif Tissue Int (2013) 0.75
Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials. Osteoporos Int (2016) 0.75
Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03. J Bone Miner Metab (2016) 0.75
Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study. J Bone Miner Metab (2015) 0.75
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79
Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care (1986) 22.65
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab (2010) 13.29
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Estimates of optimal vitamin D status. Osteoporos Int (2005) 7.13
Clinical practice. Vitamin D insufficiency. N Engl J Med (2011) 6.84
Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA (2005) 5.95
The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med (2006) 5.69
Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab (2005) 5.64
Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc (2003) 4.44
Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab (2000) 3.68
Serum vitamin D concentrations among elderly people in Europe. Lancet (1995) 3.19
A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab (2001) 3.16
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res (1996) 2.59
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res (2008) 1.78
Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J Am Geriatr Soc (2007) 1.63
Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med (2006) 1.55
Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int (2008) 1.26
Optimal vitamin D status for the prevention and treatment of osteoporosis. Drugs Aging (2007) 1.17
Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res (2006) 1.13
Recent developments in vitamin D deficiency and muscle weakness among elderly people. BMJ (2005) 1.05
Vitamin D insufficiency does not affect response of bone mineral density to alendronate. Osteoporos Int (2008) 1.00
Osteoporosis treatment and fracture incidence: the ICARO longitudinal study. Osteoporos Int (2008) 0.93
Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int (2009) 0.93
The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis. BMC Musculoskelet Disord (2007) 0.90
Screening for kidney disease in vascular patients: SCreening for Occult REnal Disease (SCORED) experience. Nephrol Dial Transplant (2009) 0.89
Vitamin D insufficiency does not affect bone mineral density response to raloxifene. J Clin Endocrinol Metab (2005) 0.85
Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women. Eur J Clin Pharmacol (1996) 0.84
The problem of low levels of vitamin D and osteoporosis: use of combination therapy with alendronic acid and colecalciferol (vitamin D3). Drugs Aging (2006) 0.80
Vitamin D and bisphosphonate response. Osteoporos Int (2014) 5.04
[Determination of enzymatic catalysis for the cis-trans-isomerization of peptide binding in proline-containing peptides]. Biomed Biochim Acta (1984) 2.80
TASK-3, a new member of the tandem pore K(+) channel family. J Biol Chem (2000) 2.29
Characterization of cspB, a Bacillus subtilis inducible cold shock gene affecting cell viability at low temperatures. J Bacteriol (1992) 2.04
Mip protein of Legionella pneumophila exhibits peptidyl-prolyl-cis/trans isomerase (PPlase) activity. Mol Microbiol (1992) 1.83
The refolding of urea-denatured ribonuclease A is catalyzed by peptidyl-prolyl cis-trans isomerase. Biochim Biophys Acta (1985) 1.75
Induction of prostaglandin E synthesis in normal and neoplastic macrophages: role for colony-stimulating factor(s) distinct from effects on myeloid progenitor cell proliferation. Proc Natl Acad Sci U S A (1979) 1.63
Limitation of excessive myelopoiesis by the intrinsic modulation of macrophage-derived prostaglandin E. Science (1978) 1.60
Statin treatment and adherence to national cholesterol guidelines after ischemic stroke. Neurology (2006) 1.57
Conformational specificity of chymotrypsin toward proline-containing substrates. Biochim Biophys Acta (1984) 1.32
Elevated serum cyclophilin levels in patients with severe sepsis. J Clin Immunol (1997) 1.28
Synergistic interaction and the role of C-terminus in the activation of TRAAK K+ channels by pressure, free fatty acids and alkali. Pflugers Arch (2001) 1.28
Localization of TREK-2 K+ channel domains that regulate channel kinetics and sensitivity to pressure, fatty acids and pHi. Pflugers Arch (2001) 1.24
Prostaglandin E2 induces receptive behaviors in female Xenopus laevis. Horm Behav (1985) 1.24
TBAK-1 and TASK-1, two-pore K(+) channel subunits: kinetic properties and expression in rat heart. Am J Physiol (1999) 1.23
Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins (1981) 1.18
Prostaglandin E inhibition of T-lymphocyte colony formation: a possible mechanism of monocyte modulation of clonal expansion. J Clin Invest (1979) 1.18
Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin. Ann Intern Med (1988) 1.07
Prostaglandin production by human blood monocytes and mouse peritoneal macrophages: synthesis dependent on in vitro culture conditions. Prostaglandins (1981) 1.01
Comparison of commercially available parathyroid hormone immunoassays in the differential diagnosis of hypercalcemia due to primary hyperparathyroidism or malignancy. Ann Intern Med (1979) 1.01
Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Diabetologia (2006) 0.98
Bone strength and related traits in HcB/Dem recombinant congenic mice. J Bone Miner Res (2001) 0.97
Lymphokine-mediated bone resorption requires endogenous prostaglandin synthesis. J Exp Med (1981) 0.97
The cis/trans interconversion of the calcium regulating hormone calcitonin is catalyzed by cyclophilin. FEBS Lett (1993) 0.96
Increased prostaglandin synthesis by macrophages from tumor-bearing mice. J Immunol (1979) 0.94
Effects of heat shock, stannous chloride, and gallium nitrate on the rat inflammatory response. Cell Stress Chaperones (2001) 0.94
Modulation of rat atrial G protein-coupled K+ channel function by phospholipids. J Physiol (1999) 0.94
Recognition of protein substrates by the prolyl isomerase trigger factor is independent of proline residues. J Mol Biol (1998) 0.93
Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest (1984) 0.92
Automatable lipid bilayer formation and ion channel measurement using sessile droplets. J Phys Condens Matter (2010) 0.92
Cloning and characterization of ppiB, a Bacillus subtilis gene which encodes a cyclosporin A-sensitive peptidyl-prolyl cis-trans isomerase. Mol Microbiol (1994) 0.91
Immunoblastic lymphadenopathy with hypercalcemia. Mt Sinai J Med (1980) 0.91
Kinetic beta-deuterium isotope effects suggest a covalent mechanism for the protein folding enzyme peptidylprolyl cis/trans-isomerase. FEBS Lett (1989) 0.90
Prostaglandin E1 inhibits collagenase gene expression in rabbit synoviocytes and human fibroblasts. Endocrinology (1992) 0.89
Microdistribution of lead in bone: a new approach. Neurotoxicology (1992) 0.88
Some insight on censored cost estimators. Stat Med (2011) 0.88
Homonuclear indor spectroscopy as a means of simplifying and analyzing proton magnetic resonance spectra of peptides and as a basis for determining secondary and tertiary conformations of complex peptides. Biochemistry (1972) 0.88
Molecular cloning and expression of a 2-arylpropionyl-coenzyme A epimerase: a key enzyme in the inversion metabolism of ibuprofen. Mol Pharmacol (1997) 0.88
Gallium increases bone calcium and crystallite perfection of hydroxyapatite. Calcif Tissue Int (1986) 0.87
Tumor necrosis factor-alpha stimulates phosphatidylinositol breakdown by phospholipase C to coordinately increase the levels of diacylglycerol, free arachidonic acid and prostaglandins in an osteoblast (MC3T3-E1) cell line. Biochim Biophys Acta (1991) 0.87
Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol (1998) 0.87
Physiological and pharmacological effects of zinc on immune response. Ann N Y Acad Sci (1990) 0.87
Leishmania major parasites express cyclophilin isoforms with an unusual interaction with calcineurin. Biochem J (1998) 0.86
Evaluation of a rapid assay for identification of Mycobacterium tuberculosis grown in solid and liquid media. Int J Tuberc Lung Dis (2011) 0.85
Studies on the proteolytic activity of gamma-globulin preparations. Biochem J (1967) 0.85
Stage-dependent reduction in T colony formation in Hodgkin's disease. Coincidence with monocyte synthesis of prostaglandins. J Clin Invest (1980) 0.85
Effect of gallium on bone mineral properties. Calcif Tissue Int (1988) 0.85
A review of calcium preparations. Nutr Rev (1994) 0.84
Cyclophilin-A is a zinc-dependent DNA binding protein in macrophages. FEBS Lett (1995) 0.84
A review of clinical trials of therapies for osteoporosis using fracture as an end point. J Clin Densitom (1999) 0.84
Streptomycetes possess peptidyl-prolyl cis-trans isomerases that strongly resemble cyclophilins from eukaryotic organisms. Mol Microbiol (1992) 0.83
Gallium nitrate for acute treatment of cancer-related hypercalcemia: clinicopharmacological and dose response analysis. Cancer Res (1986) 0.83
Opposite regulation of tissue factor expression by calcineurin in monocytes and endothelial cells. J Immunol (2001) 0.83
Maintenance etidronate in the prevention of malignancy-associated hypercalcemia. Arch Intern Med (1987) 0.82
Measles in Europe in 2001-2002. Euro Surveill (2003) 0.82
Host-cell cyclophilin is important for the intracellular replication of Leishmania major. Mol Microbiol (1997) 0.81
Characterization of the electrophysiological, biochemical and behavioral actions of epibatidine. J Pharmacol Exp Ther (1995) 0.81
Protein kinases A and C positively regulate G protein-dependent activation of phosphatidylinositol-specific phospholipase C by tumor necrosis factor-alpha in MC3T3-E1 osteoblasts. J Cell Biochem (1997) 0.81
Gallium nitrate inhibits accelerated bone turnover in patients with bone metastases. J Clin Oncol (1987) 0.80
A constitutive 65 kDa chondrocyte protein as a target antigen in adjuvant arthritis in Lewis rats. Autoimmunity (1994) 0.80
Measles is still a cause for concern in Europe. Euro Surveill (2008) 0.80
A simple modification of the Peppel/Baglioni method for RNA isolation from cell culture. Biotechniques (1992) 0.79
Gallium nitrate for advanced Paget disease of bone: effectiveness and dose-response analysis. Ann Intern Med (1990) 0.79
Metabolic effects of gallium nitrate administered by prolonged infusion. Cancer Treat Rep (1985) 0.79
Distinguishing features of primary hyperparathyroidism in patients with breast cancer. Cancer (1987) 0.79
Expression of Ca2+ -activated K+ channels in human dermal fibroblasts and their roles in apoptosis. Skin Pharmacol Physiol (2009) 0.79
Gallium nitrate for treatment of refractory hypercalcemia from parathyroid carcinoma. Ann Intern Med (1987) 0.79
Multivariate analysis of T-cell functional defects and circulating serum factors in Hodgkin's disease. Cancer (1981) 0.79
Hypercalcaemia in malignancy. Clin Endocrinol Metab (1980) 0.78
Prostaglandins in cancer: a review. Cancer Invest (1983) 0.77
Bone particles from gallium-treated rats are resistant to resorption in vivo. Bone Miner (1991) 0.77
Gallium nitrate regulates rat osteoblast expression of osteocalcin protein and mRNA levels. J Bone Miner Res (1993) 0.77
Nitric oxide stimulates a large-conductance Ca-activated K+ channel in human skin fibroblasts through protein kinase G pathway. Skin Pharmacol Physiol (2005) 0.77
Glial growth factor-2 promotes the survival, migration and bromodeoxyuridine incorporation of mammalian neural crest cells in caudal neural tube explant cultures. Brain Res Dev Brain Res (2000) 0.76
Role of protein kinase A in collagenase-1 gene regulation by prostaglandin E1: studies in a rabbit synoviocyte cell line, HIG-82. J Bone Miner Res (1997) 0.76
Peptidyl-prolyl cis-trans isomerase from Bacillus subtilis. A prokaryotic enzyme that is highly sensitive to cyclosporin A. FEBS Lett (1992) 0.76
Alpha-fodrin as a putative autoantigen in Graves' ophthalmopathy. Clin Exp Immunol (2005) 0.76
Effect of calcium citrate supplementation on urinary calcium oxalate saturation in female stone formers: implications for prevention of osteoporosis. Am J Clin Nutr (1994) 0.75
Protein kinase C-independent activation of a novel nonspecific phospholipase C pathway by phorbol myristate acetate releases arachidonic acid for prostaglandin synthesis in MC3T3-E1 osteoblasts. Prostaglandins (1997) 0.75
Etidronate for postmenopausal osteoporosis. N Engl J Med (1990) 0.75
Weak inhibitors of cyclooxygenases may exert their antinociceptive effect by modulation of transcription factors. Adv Exp Med Biol (1997) 0.75
Subtilopeptidase a cleavage in the cyclic region of the peptide antibiotic polymyxin B1. Int J Pept Protein Res (1973) 0.75
Clinical insights from the etiopathology of osteoporosis. Contemp Intern Med (1995) 0.75
Characterization of prostaglandin endoperoxide synthase from a human cell line. Biochim Biophys Acta (1986) 0.75
Diagnosis and management of osteoporosis. Contemp Intern Med (1995) 0.75
Pertussis toxin-sensitive and insensitive G proteins mediate ALFL4- stimulated release of inositol phosphates, diglycerides and arachidonic acid in MC3T3-E1 osteoblasts. Prostaglandins Leukot Essent Fatty Acids (1994) 0.75
Effects of ATP on TTX-sensitive and TTX-resistant sodium currents in rat sensory neurons. Neuroreport (2001) 0.75
Activators of protein kinase A decrease the levels of free arachidonic acid in osteoblasts via stimulation of phosphatidylcholine and phosphatidylethanolamine synthesis. Prostaglandins Leukot Essent Fatty Acids (1998) 0.75
Drug distribution under national health insurance plans. J Am Pharm Assoc (1965) 0.75
Fatty acid-induced modifications of mouse mammary alveolar lesions in organ culture. Carcinogenesis (1984) 0.75
Fit for life? Evolution of chaperones and folding catalysts parallels the development of complex organisms. Cell Stress Chaperones (1997) 0.75
The membrane as transducer in peptide hormone action. J Supramol Struct (1973) 0.75
Interaction of cyclophilin and cyclosporins monitored by affinity capillary electrophoresis. J Chromatogr A (1999) 0.75
Creating an online atlas of Salmonella serotypes in Europe. Euro Surveill (2008) 0.75
In vivo and in vitro biological activities of two human cell lines derived from anaplastic lung cancers. Cancer Res (1983) 0.75
Evaluation of PCR-reverse blot hybridization assay for the differentiation and identification of Mycobacterium species in liquid cultures. J Appl Microbiol (2014) 0.75
Prostaglandin regulation of reproductive behaviors in female Xenopus laevis: sources and target sites. Adv Prostaglandin Thromboxane Leukot Res (1987) 0.75
Medical treatment for Paget's disease of bone. Instr Course Lect (1993) 0.75